The error was in the table of the consolidated cash flow on page 13; "Consolidated cash flow statement for the period". The incorrect version stated that:

1. The company's bridge loan of SEK 12.5 million was reported in the original report under "Cash paid to suppliers and employees" and not as "Proceeds from borrowings".

2. On the penultimate row of the table, "Cash and cash equivalents at the beginning of the period", in the three-month column (04/01/24-06/30/24), 30,230 were originally reported. The correct figure is 15,653.

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 - (0)705 - 90 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold directly or through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-08-2024 15:30 CET.